Related Experiment Video

Updated: Dec 30, 2025

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

10.3K

Rho GTPases: Promising candidates for overcoming chemotherapeutic resistance

Chun-Wen Zheng1, Rui-Jie Zeng1, Li-Yan Xu2

  • 1Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, 515041, China; The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, China.

Cancer Letters
|January 26, 2020
PubMed

Insights

Rho GTPases, particularly Rac1, play a key role in chemotherapy resistance in cancer. Targeting these proteins offers a promising strategy to improve cancer treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Chemotherapy resistance is a significant obstacle in cancer treatment.
  • Rho GTPases are implicated in cancer development and progression.
  • Existing research links Rho GTPases to the mechanisms of chemoresistance.

Purpose of the Study:

  • To review the role of Rho GTPases in regulating chemoresistance.
  • To elucidate the mechanisms by which Rho GTPases influence chemotherapy response.
  • To explore Rho GTPase inhibitors as potential therapeutic strategies.

Main Methods:

  • Literature review focusing on Rho GTPases and chemoresistance.
  • Analysis of studies investigating Rho GTPase function in cancer cells.
  • Examination of available inhibitors targeting Rho GTPase pathways.

Main Results:

  • Rho GTPases, especially Rac1, are crucial regulators of chemoresistance.
  • These proteins modulate pathways that protect cancer cells from chemotherapeutic agents.
  • Specific inhibitors targeting Rho GTPases show potential in overcoming resistance.

Conclusions:

  • Understanding Rho GTPase mechanisms is key to overcoming chemoresistance.
  • Targeting Rho GTPases presents a viable strategy for novel cancer therapies.
  • Further research into Rho GTPase inhibitors may lead to improved treatment outcomes.
Keywords:
Cell signalingChemoresistanceInhibitorRac1Targeted therapy

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.1K
GTPases and their Regulation02:14

GTPases and their Regulation

Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒  small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
9.6K
GTPases and their Regulation02:14

GTPases and their Regulation

2.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
10.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K